A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2

被引:33
作者
Bera, TK [1 ]
Onda, M [1 ]
Brinkmann, U [1 ]
Pastan, I [1 ]
机构
[1] NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA
关键词
antibody engineering; bivalent dsFv; cancer therapy;
D O I
10.1006/jmbi.1998.1948
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have used protein engineering to generate a stable bivalent Fv molecule of the anti-erbB2 monoclonal antibody e23. The V-H and V-L domains of the Fv are Linked to each other by a disulfide bond and the two Fvs are connected by a flexible 15 amino acid residue (Gly(4)-Ser)(3) linker. The e23 (dsFv)(2) molecule is fused to a truncated form of Pseudomonas exotoxin to generate a bivalent disulfide-stabilized, (dsFv)(2), immunotoxin. The immunotoxin was expressed in Escherichia coli, refolded in vitro and purified to about 95% purity. Binding studies demonstrated that the (dsFv)(2) molecule has a much higher affinity for erbB2 than a monovalent dsFv molecule and a similar binding affinity as the parental antibody e23. The (dsFv)(2) immunotoxin was 5 to 20-fold more cytotoxic to two e23 antigen-positive cell Lines than the monovalent dsFv immunotoxin. The bivalent dsFv molecule is very stable, retaining 94% of its activity after a 24 hours incubation in human serum at 37 degrees C. Two other molecules with shorter linkers five and ten amino acid residues in length were produced and showed similar activities as the molecule containing a 15 amino acid residue linker. The bivalency, stability and the relative ease of purification makes these e23 (dsFv)(2) molecules valuable reagents for cancer immunotherapy and diagnosis.
引用
收藏
页码:475 / 483
页数:9
相关论文
共 51 条
[1]  
ADAMS GP, 1995, J NUCL MED, V36, P2276
[2]  
ADAMS GP, 1993, CANCER RES, V53, P4026
[3]   ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - REVIEW [J].
BAGSHAWE, KD ;
SHARMA, SK ;
SPRINGER, CJ ;
ROGERS, GT .
ANNALS OF ONCOLOGY, 1994, 5 (10) :879-891
[4]   SINGLE-CHAIN ANTIGEN-BINDING PROTEINS [J].
BIRD, RE ;
HARDMAN, KD ;
JACOBSON, JW ;
JOHNSON, S ;
KAUFMAN, BM ;
LEE, SM ;
LEE, T ;
POPE, SH ;
RIORDAN, GS ;
WHITLOW, M .
SCIENCE, 1988, 242 (4877) :423-426
[5]  
BJORK I, 1971, BIOCHEMISTRY-US, V10, P1289
[6]   A RECOMBINANT IMMUNOTOXIN CONTAINING A DISULFIDE-STABILIZED FV FRAGMENT [J].
BRINKMANN, U ;
REITER, Y ;
JUNG, SH ;
LEE, B ;
PASTAN, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (16) :7538-7542
[7]   IMMUNOTOXINS AGAINST CANCER [J].
BRINKMANN, U ;
PASTAN, I .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1994, 1198 (01) :27-45
[8]   B3(FV)-PE38KDEL, A SINGLE-CHAIN IMMUNOTOXIN THAT CAUSES COMPLETE REGRESSION OF A HUMAN CARCINOMA IN MICE [J].
BRINKMANN, U ;
PAI, LH ;
FITZGERALD, DJ ;
WILLINGHAM, M ;
PASTAN, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8616-8620
[9]  
Brinkmann Ulrich, 1995, Methods (Orlando), V8, P143, DOI 10.1006/meth.1995.9992
[10]   A METHOD FOR INCREASING THE YIELD OF PROPERLY FOLDED RECOMBINANT FUSION PROTEINS - SINGLE-CHAIN IMMUNOTOXINS FROM RENATURATION OF BACTERIAL INCLUSION-BODIES [J].
BUCHNER, J ;
PASTAN, I ;
BRINKMANN, U .
ANALYTICAL BIOCHEMISTRY, 1992, 205 (02) :263-270